Alnylam States Preclinical Data - Analyst Blog

A generic image of a monitor with Market Analysis displayed
Credit: Shutterstock photo

Alnylam Pharmaceuticals Inc ( ALNY ) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington's disease ( HD ). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system ( CNS ) distribution and robust therapeutic silencing of the gene responsible for Huntington's disease. Further, ALN-HTT was well tolerated in these studies.

ALN-HTT is being developed in collaboration with Medtronic, Inc. ( MDT ) and the CHDI Foundation. Alnylam expects to file an investigational new drug application ( IND ) application for the candidate in 2012. Approval of the IND by the US Food & Drug Administration (FDA) will allow the candidate to enter early stage clinical trials.

Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancer through existing or future partnerships. Alnylam's core product strategy however is Alnylam 5x15 which aims at developing products for treating genetically defined diseases with unmet medical needs using the ground-breaking RNAi technology. Alnylam expects to have five such RNAi therapeutic programs in advanced clinical development by the end of 2015. Four programs are in pre-clinical/clinical stages of development including ALN-PCS (for hypercholesterolemia), second generation ALN-TTR (ATTR), ALN-HPN (refractory anemia) and ALN-APC (hemophilia). ALN-HTT makes up the fifth candidate.

Our Recommendation

We currently have an Outperform recommendation on Alnylam. The stock carries a Zacks #2 Rank ("Buy") in the short term. We like the company's "5X15" initiative and also the pipeline progress at Alnylam. We believe that 2012 will be an important year for the company due to significant clinical catalysts. Moreover, the company has collaborated with some big pharmaceutical players, such as Roche ( RHHBY ), Biogen ( BIIB ), Medtronic, Takeda, Kyowa Hakko Kirin, Cubist Pharmaceuticals ( CBST ) and Isis Pharmaceuticals ( ISIS ), to further develop and utilize its core technology. These partnerships further validate the potential and viability of the RNAi approach.

ALNYLAM PHARMA ( ALNY ): Free Stock Analysis Report

BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report

CUBIST PHARM (CBST): Free Stock Analysis Report

ISIS PHARMACEUT (ISIS): Free Stock Analysis Report

MEDTRONIC (MDT): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More